Processed and formatted by SEC Watch - Visit SECWatch.

com

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

February 19, 2009

(Date of earliest event reported)

PHARMACYCLICS, INC.

(Exact name of registrant as specified in its charter)

Delaware 000-26658 94-3148201

(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification Number)

995 E. Arques Avenue

Sunnyvale, California 94085-4521
(408) 774-0330

(Address of principal executive offices including zip code and registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 Processed and formatted by SEC Watch - Visit SECWatch.com

Item 1.01 Entry into a Material Definitive Agreement.

See the disclosures set forth under Item 3.02 which are incorporated by reference into this Item 1.01.

Item 3.02 Unregistered Sales of Equity Securities.

On February 19, 2009, Pharmacyclics, Inc. (the "Registrant") sold approximately 1.5 million shares (the "Shares") of the Registrant's common
stock, par value $0.0001 per share, at $0.93 per share for an aggregate purchase price of approximately $1.4 million. The purchasers of the
Shares are certain foreign and U.S. individuals and entities who are principals of Pacific Biopharma Group, Ltd. ("PBG"), a Cayman Islands
company located in San Bruno California and Taizhou, Jiangsu Province, People's Republic of China. Glenn Rice, our President and Chief
Operating Officer, is a principal of PBG, but did not participate in the transaction.

The sale of the Shares as described above were deemed to be exempt from registration pursuant to Section 4(2) of the Securities Act of 1933,
as amended, and Regulation S promulgated thereunder ("Regulation S"), as transactions by an issuer not involving a public offering. The
recipients of the Shares represented their intention to acquire the securities for investment only and not with a view to or for sale in
connection with any distribution thereof and appropriate legends were affixed to the share certificates and instruments issued in the sale of
Shares. All recipients either received adequate information about the Registrant or had adequate access, through their relationship with the
Registrant, to information about the Registrant. In addition, the Non-U.S. investors also represented to the Registrant all appropriate
representations required by Regulation S and the Registrant complied with all appropriate provisions of Regulation S.

Item 8.01 Other Events.

On February 20, 2009, the Registrant issued a press related to the matters set forth in Items 1.01 and 3.02. A copy of the press release is
attached to this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.
Exhibit No. Description

99.1 Press Release of Pharmacyclics, Inc. dated February 20, 2009.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

Date: February 20, 2009

PHARMACYCLICS, INC.
By: /s/ ROBERT W. DUGGAN
Name: Robert W. Duggan
Title: Chairman and Chief Executive Officer

INDEX TO EXHIBITS
Exhibit Description

99.1 Press Release of Pharmacyclics, Inc. dated February 20, 2009. PDF
 Processed and formatted by SEC Watch - Visit SECWatch.com
PDF Also provided in PDF as a courtesy.

EXHIBIT 99.1

Contacts:
Ramses Erdtmann
Pharmacyclics, Inc.
(408) 215-3325

Carolyn Wang
WeissComm Partners
(415) 946-1065

PHARMACYCLICS, INC. ANNOUNCES CLOSING OF A PRIVATE FINANCING WITH THE PRINCIPALS OF PACIFIC BIOPHARMA
GROUP, LTD.

Sunnyvale, CA USA February 20, 2009: Pharmacyclics (NASDAQ:PCYC) announced today the close of a financing in connection with an
investment by the principals of Pacific Biopharma Group, Ltd. (PBG), located in San Bruno California and Taizhou, Jiangsu Province, People's
Republic of China. The transaction was structured as an approximately $1.4 million dollar private investment into Pharmacyclics at $0.93/share.
Robert Duggan, CEO of Pharmacyclics noted, "We appreciate the vote of confidence by the principals of PBG, all extremely successful
biotech, pharmaceutical and/or generic drug industry executives who have separately built three billion dollar plus companies. We are in active
communication with the principals of PBG discussing collaborative opportunities including terms & conditions around which we may choose
to in- license an early stage Phase II drug. We look forward to a fruitful relationship."

Pharmacyclics currently has four drugs in Phase I to Phase III clinical development for cancer. This includes a leading histone deacetylase
inhibitor (PCI- 24781) for multiple cancers; an inhibitor of Factor VIIa (PCI- 27483) targeting pancreatic, gastric, colon and breast cancers; a first
in class inhibitor of Bruton's tyrosine kinase (Btk) (PCI-32765) currently in a Phase 1 clinical trial and targeting B-cell related oncology
applications; a Btk inhibitor in advanced preclinical testing (PCI-45261) targeting autoimmune and allergic indications; and an HDAC-8
inhibitor (PCI-34051) for autoimmune and cancer indications. Motexafin gadolinium (MGd) has completed two Phase III trials in patients with
brain metastases from non-small- cell lung cancer (NSCLC) and other cancers and is currently in a Phase II trial for glioblastoma.

ABOUT PHARMACYCLICS

Pharmacyclics is committed to creating and developing novel pharmaceutical products that treat serious unmet medical needs in oncology and
autoimmune diseases. Its deep and broad pipeline includes four innovative drug candidates that are currently under clinical development. The
Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how
Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

ABOUT PACIFIC BIOPHARMA GROUP

PBG is an oncology development company focused on development of drugs to treat pediatric cancer, small cell lung cancer and melanoma.
PBG was founded by distinguished pharmaceutical executives, with research centers in the United States and China Medical City. It is
headquartered in San Bruno, CA and in Taizhou, Jiangsu Province at the China Medical City complex.

NOTE: Other than statements of historical fact, the statements made in this press release about enrollment and future plans for our clinical
trials, progress of and reports of results from preclinical and clinical studies, clinical development plans and product development and
corporate partnering activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The forward-
looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ
materially from those in the forward-looking statements. For further information about these risks and other factors that may affect the actual
results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to
time, including but not limited to its quarterly report on Form 10-Q for the period ended December 31, 2008. Forward-looking statements
contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise.

###
Processed and formatted by SEC Watch - Visit SECWatch.com